Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00918008 · ClinicalTrials.gov registry record

A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer

A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.

Terminated
Registry status
12
Enrollment target

NCT00918008: Clinical Trial study, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00918008 is a clinical trial that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00918008 was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.

TERMINATED
Registry status
12 participants
Enrollment target

Study Summary

The purposes of this study is to evaluate a new genetic-based test which will identify patients diagnosed with muscle-invasive bladder cancer before their surgery, who might have specific genes, which will increase their chances of recurrence of cancer after their surgery. Some patients who are diagnosed with bladder cancer and have their had bladder removed, will have a recurrence of cancer sometime after their surgery. This recurrence is usually caused by tumor cells that originated from the bladder tumor and traveled to other parts of the body, which is called metastatic cancer. Some patients are more likely than others to have metastatic disease. This test may help in identifying these patients who might develop metastases from having these specific genes.

Interventions

  • GENETIC Blood draw

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2009-06
Est. Completion 2011-05
Memorial Sloan Kettering Cancer Center

1,884 total trials

Why NCT00918008 stopped before completion

NCT00918008 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.

NCT00918008 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00918008 about?

NCT00918008 is a clinical study titled "A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer". The purposes of this study is to evaluate a new genetic-based test which will identify patients diagnosed with muscle-invasive bladder cancer before their surgery, who might have specific genes, which will increase their chances of recurrence of cancer after their surgery. Some patients who are dia...

What is the current status of trial NCT00918008?

This trial is currently terminated. The enrollment target is 12 participants. The study started on 2009-06. Estimated completion is 2011-05.

What interventions are being tested in trial NCT00918008?

The interventions under investigation include: Blood draw (GENETIC).

Who is sponsoring clinical trial NCT00918008?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00918008, the US trial registry maintained by the National Library of Medicine. NCT00918008 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.